The research on proton pump inhibitors (PPIs) and dementia has become deeply contradictory, making it difficult for patients and caregivers to know what to believe. One major meta-analysis of over 642,000 patients found no association between PPI use and dementia risk, while another meta-analysis of 166,000 participants published the same year concluded that PPI users faced significantly elevated dementia risk. A 2025 umbrella review examining 11 systematic reviews and 21 studies found that only one high-quality analysis showed a meaningful connection—the rest did not. This fragmentation reflects a genuine scientific puzzle: the evidence honestly points in different directions depending on which studies researchers examine and which populations they focus on. What makes this more challenging is that PPIs are among the most widely prescribed medications globally. Millions of people take them daily for acid reflux, GERD, and ulcer prevention.
When conflicting research suggests a possible link to cognitive decline, patients and their families reasonably ask whether the medication that’s helping their digestion might be harming their brain. The honest answer is that we don’t yet know if there is a direct causal link, which is precisely what the conflicting studies mean. The stakes matter because PPI use often continues for years or decades. People aren’t taking these medications for short-term symptom relief; many use them continuously. If there truly were a dementia risk, the long-term exposure would compound the concern. But if the apparent risk is an artifact of how studies were designed or which populations were studied, then avoiding these medications unnecessarily could leave people suffering from uncontrolled reflux and its own complications.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Do Proton Pump Inhibitors Actually Increase Dementia Risk?
- How Studies Have Reached Opposite Conclusions on PPI Use and Dementia
- Could Proton Pump Inhibitors Actually Protect Against Dementia?
- Understanding Proposed Mechanisms: How Might PPIs Affect the Brain?
- Which Populations Face Greater Risk?
- What the FDA Actually Warns About PPI Use
- Interpreting Conflicting Evidence: What It Means for Your Decisions
- Frequently Asked Questions
Do Proton Pump Inhibitors Actually Increase Dementia Risk?
In 2019, two major meta-analyses attempted to settle this question by pooling data from multiple studies—and arrived at opposite conclusions. The first, analyzing 642,305 patients, found that PPI users had essentially the same dementia risk as non-users (hazard ratio of 1.04, with confidence intervals spanning 0.92–1.15, meaning the results could not reliably distinguish between slightly increased or slightly decreased risk). For Alzheimer’s disease specifically, the hazard ratio was 0.96, suggesting no association at all. But the second 2019 meta-analysis, examining 166,146 participants across six studies, reported that PPI users faced a 29% increased dementia risk (hazard ratio of 1.29), a statistically significant difference. Both were published in respected medical journals. Both followed rigorous meta-analytic methods. Yet they reached opposite conclusions about the same fundamental question.
This direct contradiction reveals a core problem in studying this association: different studies used different populations, followed patients for different lengths of time, defined dementia diagnosis differently, and adjusted for different confounding factors. A person taking a PPI might also be taking other medications, might have different lifestyle factors, or might have health conditions that independently affect dementia risk. Teasing apart which factor caused what becomes extremely difficult when you’re comparing people across decades and continents. The larger 2019 meta-analysis that found no association had greater statistical power simply by including more patients, yet that’s not necessarily a guarantee of accuracy if the included studies had systematic biases in how they recruited or followed participants. A third layer was added in 2025 when researchers conducted an umbrella review—essentially a review of reviews—examining all 11 systematic reviews and meta-analyses on this topic published between 2016 and 2024. They found that only one of the high-quality reviews identified a significant association between PPI use and dementia. None of the six reviews that specifically examined Alzheimer’s disease found an association. This latest summary of the evidence suggests the weight of rigorous analysis points toward no causal link, yet the existence of even one contradictory high-quality review means some legitimate scientific uncertainty remains.
How Studies Have Reached Opposite Conclusions on PPI Use and Dementia
One reason the evidence conflicts is that observational studies—which follow people over time but cannot randomize them to take or avoid PPIs—face inherent limitations in detecting true cause-and-effect relationships. People prescribed PPIs often have GERD or other gastrointestinal conditions that might themselves affect cognition through nutritional malabsorption or chronic inflammation. Researchers try to account for these differences statistically, but hidden factors might still differ between PPI users and non-users in ways that affect dementia risk independently of the medication itself. A person who has had severe GERD for 20 years differs in many ways from someone without GERD, and those differences might explain apparent associations better than the PPI itself. The 2025 umbrella review did identify patterns in which associations appeared more likely to emerge. Subgroup analyses suggested that dementia risk appeared elevated specifically among individuals aged 65 and older, in studies conducted in Asia and Europe (less so in North America), among people using PPIs for more than 5 years, and in higher-quality studies that controlled for more confounding factors.
That last finding is particularly interesting: the best-designed studies sometimes showed higher associations than lower-quality ones. This could mean the true association is real but small, or it could mean that higher-quality studies better accounted for confounders that themselves increase dementia risk. The geographic variation is unexplained—there’s no clear biological reason why PPIs would carry different dementia risks in different continents, which raises questions about whether unmeasured population differences are driving the observed associations. Bias analysis, a technique used in several reviews to assess whether observed associations might be entirely explained by methodological limitations rather than true effects, has been applied to the PPI-dementia question. A 2023 systematic review and bias analysis by Ahn and colleagues examined whether the observed associations could be explained by bias alone and found that unmeasured confounding or misclassification bias might largely or entirely explain the associations that studies reported. In plainer terms: the apparent link between PPIs and dementia risk might not reflect actual PPI harm but rather differences between PPI users and non-users that researchers couldn’t fully measure and adjust for.
Could Proton Pump Inhibitors Actually Protect Against Dementia?
One of the most surprising findings came from a large Welsh cohort study using linked national health records across the United Kingdom. Rather than finding increased dementia risk among PPI users, this study found a 33% *decreased* risk (hazard ratio of 0.67, tightly bounded by confidence intervals of 0.65–0.67). This is the opposite direction from the studies claiming PPIs increase dementia risk. The Welsh study was large and used electronic health records, reducing the chance of people misremembering whether they took medications or whether they’d been diagnosed with dementia. Yet this finding stands in direct contradiction to meta-analyses concluding that PPIs increase risk, creating a genuine puzzle about which evidence to trust. A 2024 Mendelian randomization study published in Nature’s Scientific Reports added another perspective: using genetic variants that predispose people to require PPIs as a natural experiment, researchers found no genetic evidence that PPI use causes dementia.
Mendelian randomization attempts to circumvent observational study bias by using genetics as a proxy for exposure, reducing the influence of confounding factors that might bias traditional observational studies. That this genetic-proxy approach found no association suggests that if an observational link exists, confounding factors rather than the PPI itself might be responsible. Yet genetic approaches also have limitations—genetic variants that relate to PPI need don’t perfectly predict PPI use, and people with genetic risk for conditions requiring PPIs might differ in other ways that affect dementia risk. These contradictory findings create a genuine dilemma for interpretation. If PPIs reduced dementia risk as the Welsh study suggests, public health efforts might encourage PPI use in older adults at dementia risk. If PPIs increase risk as some meta-analyses claim, the prescription calculus changes entirely. The fact that high-quality evidence produces opposite conclusions suggests that either the true effect is extremely small (and therefore difficult to detect reliably), or systematic differences between how studies recruited participants, defined outcomes, or followed people over time are creating apparent effects that don’t reflect true causality.
Understanding Proposed Mechanisms: How Might PPIs Affect the Brain?
If PPIs do influence dementia risk, researchers have proposed two main mechanisms. The first focuses on vitamin B12: PPIs work by suppressing gastric acid, which is necessary to release B12 from food proteins so the intestine can absorb it. Over years or decades of PPI use, some patients develop B12 deficiency. B12-deficient individuals show elevated levels of homocysteine (an amino acid associated with vascular and neurological damage), and high homocysteine is linked to tau hyperphosphorylation and amyloid-beta deposition—the pathological hallmarks of Alzheimer’s disease. Research suggests that B12-deficient individuals have approximately 1.5 times higher risk of cognitive impairment compared to those with normal B12 levels. On the surface, this offers a plausible biological pathway connecting PPIs to dementia risk. However, B12 deficiency from PPI use develops in only a subset of long-term users, and many people on PPIs maintain normal B12 levels despite years of therapy. The second proposed mechanism suggests PPIs might have direct effects on the brain itself, independent of B12.
Some research indicates that PPIs might cross the blood-brain barrier and influence amyloid-beta metabolism, tau pathology, neuroinflammation, synaptic function, mitochondrial health, and oxidative stress. This would represent a direct toxic or dysregulatory effect on brain cells rather than an indirect effect mediated through nutritional deficiency. If true, it would mean that maintaining normal B12 levels wouldn’t fully protect against PPI-related cognitive decline. Neither mechanism has been definitively established in humans, and the evidence for both is primarily observational or derived from animal models and cell studies rather than rigorous clinical trials. The challenge with both proposed mechanisms is that they’re speculative in the absence of direct evidence from intervention trials. Animal models can show that PPI use alters brain chemistry, but animals aren’t humans. Observational evidence that PPI users have different biomarkers doesn’t prove the PPIs caused those differences. And the biological plausibility of a mechanism doesn’t guarantee it operates meaningfully in the real world at the doses used clinically. Both mechanisms remain scientifically interesting but unproven as explanations for any true PPI-dementia association.
Which Populations Face Greater Risk?
If PPI use does increase dementia risk, it doesn’t appear to affect all populations equally. The 2025 umbrella review identified several subgroups where associations appeared more pronounced. People aged 65 and older showed elevated risk in several analyses—younger users in the same studies sometimes showed no association. This age-stratified finding makes biological sense, as older brains with existing amyloid and tau pathology might be more vulnerable to additional insults, but it also complicates the risk picture since people over 65 are precisely the group most likely to be on long-term PPI therapy for chronic GERD. Geographic patterns emerged as well, with studies from Asia and Europe reporting stronger associations than North American studies. This variation is difficult to explain biologically and raises the possibility that differences in PPI prescribing patterns, diagnosis of dementia, study design, or unmeasured population characteristics are driving the apparent geographic variation.
A medication’s real-world effect shouldn’t fundamentally differ by continent unless genetic, environmental, or healthcare-system factors differ substantially—and those differences aren’t well characterized. Similarly, longer PPI duration appeared associated with higher dementia risk in subgroup analyses, suggesting that any effect, if real, might accumulate over time rather than appear immediately. Someone taking a PPI for one year faces a different risk calculus than someone on it for ten years. Higher-quality studies, paradoxically, were more likely to report associations than lower-quality studies—the opposite of what you’d expect if bias were entirely responsible. This counterintuitive finding suggests either that better-designed studies truly capture a real effect more accurately, or that certain types of methodological rigor (such as adjustment for particular confounders) reveal associations that are actually artifacts of specific analytical choices. Disentangling which explanation is correct requires expertise in epidemiological methodology and may ultimately be unknowable without experimental data.
What the FDA Actually Warns About PPI Use
The Food and Drug Administration has issued safety communications about PPIs, but these warnings focus specifically on mineral and electrolyte deficiencies—low magnesium, calcium, and vitamin B12—rather than dementia. These mineral effects are well-established and happen to a meaningful proportion of long-term users. Low magnesium can cause muscle weakness and arrhythmias. Low calcium might affect bone density. The FDA’s explicit warnings don’t mention dementia or cognitive decline, reflecting the agency’s assessment that evidence of dementia risk is insufficient to warrant an official warning.
This doesn’t mean PPIs are safe regarding cognition; it means the evidence base doesn’t meet the FDA’s threshold for recommending a new warning label. Notably, the absence of an FDA warning on dementia coexists with genuine scientific debate in the medical literature. The FDA sets a high bar for adding warnings—typically requiring consistent, replicated evidence of harm—and the conflicting PPI-dementia studies clearly don’t meet that threshold. But medical practitioners and patients are reasonably asking the question even in the absence of an official FDA statement. The gap between what researchers are publishing and what the FDA has officially warned about reflects the genuine uncertainty in the evidence.
Interpreting Conflicting Evidence: What It Means for Your Decisions
When major medical organizations publish contradictory findings on the same question, people often ask which study to believe or whether one side must be wrong. In reality, conflicting evidence usually means something more nuanced: the true effect is either very small, or it exists only in specific populations, or methodological factors are creating apparent effects that don’t reflect true causality. The PPI-dementia literature contains all three possibilities, which is why no clear consensus has emerged despite years of research.
For someone currently taking a PPI for legitimate gastroenterological reasons—documented GERD, peptic ulcer disease, or Barrett’s esophagus—the decision to continue therapy can’t hinge on speculative dementia risk when the evidence is this contradictory. Uncontrolled GERD carries its own risks, including aspiration, esophageal damage, and reduced quality of life from chronic symptoms. Stopping a PPI based on preliminary or contradictory evidence of dementia risk might create a new problem—worsening gastrointestinal disease—in an attempt to prevent a potential problem that may not exist. What the evidence does support is monitoring for B12 deficiency in people on long-term PPIs (B12 levels can be checked by blood test), discussing with healthcare providers whether the lowest effective PPI dose is being used, and reconsidering whether PPI therapy is still necessary for people whose GERD may have improved over time.
Frequently Asked Questions
Should I stop taking my PPI because of dementia risk?
Not based on current evidence. Multiple high-quality studies found no association between PPIs and dementia. If you have a documented reason for PPI therapy, discuss your concerns with your doctor rather than stopping without medical guidance.
Is vitamin B12 deficiency the real connection between PPIs and dementia?
It’s one proposed mechanism, but it’s not established. B12 deficiency can affect cognition, and PPIs do reduce B12 absorption in some users. However, most long-term PPI users maintain normal B12 levels, and the mechanism alone doesn’t explain all observed associations in studies.
Why do different studies reach opposite conclusions?
Studies used different populations, follow-up lengths, dementia definitions, and adjusted for different confounding factors. People taking PPIs often have other health conditions that also affect dementia risk, making it difficult to isolate the PPI’s true effect.
Could PPIs actually protect against dementia?
One large Welsh cohort study found PPI users had lower dementia risk than non-users. This contradicts other findings, which is why the evidence is called conflicting. It likely reflects different study populations and methods rather than true protection.
What should long-term PPI users do?
Ask your doctor about B12 monitoring, discuss whether your PPI dose is appropriate for your current needs, and revisit periodically whether PPI therapy is still necessary. Don’t make medication changes based on preliminary research without medical consultation.
Why hasn’t the FDA warned about dementia and PPIs?
The evidence doesn’t meet the FDA’s threshold for an official warning. Conflicting research findings in the medical literature don’t translate to regulatory action unless evidence is consistent and strong.
